医学
免疫学
支原体
CXCL2型
炎症
重组DNA
哮喘
病理
趋化因子
结核分枝杆菌
生物
肺结核
基因
趋化因子受体
生物化学
作者
Ling Chen,Sheng Guo,Liangxia Wu,Jianhua Zhang
标识
DOI:10.3760/cma.j.issn.1673-4408.2019.07.017
摘要
Objective
To observe the effects of intranasal inoculation with recombinant Mycobacterium smegmatis (rMS) on the airway inflammation of non-eosinophilic asthmatic mouse and further investigate the relative mechanism.
Methods
DO11.10 T-cell receptor transgenic mice were divided randomly into three groups.Non-eosinophilic asthmatic model was established via OVA challenge, rMS were administrated into mice before challenge.Anti-IL-17A autoantibody in sera, IL-6 and IL-17A in BALF were measured by ELISA, the proportion of neutrophil in BALF was measured by FCM, MPO activity in lung tissue was detected by colorimetry, and the mRNA expression of CXCL2 and CXCL5 was measured by real-time PCR.
Results
Compared to control group, the number of neutrophils, IL-6 and IL-17A levels in BALF from asthmatic mice was significantly increased, meanwhile MPO activity and the expression of CXCL2, CXCL5 in lung tissue were both significantly upregulated.The results showed that high titer of autoantibody of IL-17A in sera of mice vaccined with recombinant Mycobacterium smegmatis was detected.Compared to asthma group, neutrophils and IL-6, IL-17A in BALF were significantly decreased, meanwhile MPO activity and CXCL2, CXL5 mRNA expression were significantly down-regulated.
Conclusion
Recombinant Mycobacterium smegmatis exhibits anti-inflammatory activity in murine neutrophilic asthma model and it may have protective effects on asthma.
Key words:
Bronchial asthma; IL-17A; Autoantibody; Airway inflammation
科研通智能强力驱动
Strongly Powered by AbleSci AI